Get the Stockscreener App
13.15
2.59%
-0.35
After Hours:
13.62
0.47
+3.57%
Cadrenal Therapeutics Inc stock is traded at $13.15, with a volume of 18,990.
It is down -2.59% in the last 24 hours and up +20.53% over the past month.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
See More
Previous Close:
$13.50
Open:
$13.62
24h Volume:
18,990
Relative Volume:
0.65
Market Cap:
$26.92M
Revenue:
-
Net Income/Loss:
$-4.85M
P/E Ratio:
-42.42
EPS:
-0.31
Net Cash Flow:
$-3.95M
1W Performance:
-0.72%
1M Performance:
+20.53%
6M Performance:
-25.58%
1Y Performance:
+22.90%
1-Day Range:
$13.15
$13.68
1-Week Range:
$13.00
$13.72
52-Week Range:
$8.74
$22.90
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Name
Cadrenal Therapeutics Inc
Sector
Industry
Phone
904-300-0701
Address
822 A1A NORTH, PONTE VEDRA
Compare CVKD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
13.15 | 27.12M | 0 | -4.85M | -3.95M | -0.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-23 | Initiated | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc Stock (CVKD) Latest News
Cadrenal Therapeutics Inc. stock outlook for YEAR2025 Sector Review & Fast Exit/Entry Strategy Plans - Newser
Will earnings trigger a reversal in Cadrenal Therapeutics Inc.July 2025 Review & Low Drawdown Trading Strategies - Newser
relative strength of cadrenal therapeutics inc. in sector analysis2025 Key Lessons & Consistent Growth Equity Picks - Newser
tick level data insight on cadrenal therapeutics inc. volatilityQuarterly Risk Review & High Win Rate Trade Alerts - Newser
Live market analysis of Cadrenal Therapeutics Inc.July 2025 Earnings & Fast Moving Stock Watchlists - Newser
What high frequency data says about Cadrenal Therapeutics Inc.Portfolio Value Summary & AI Forecasted Entry and Exit Points - Newser
What data driven models say about Cadrenal Therapeutics Inc.’s futureWeekly Profit Recap & Pattern Based Trade Signal System - Newser
Tick level data insight on Cadrenal Therapeutics Inc. volatilityQuarterly Market Summary & Advanced Swing Trade Entry Alerts - Newser
Intraday pattern recognizer results for Cadrenal Therapeutics Inc.July 2025 Price Swings & Capital Efficiency Focused Strategies - Newser
Is Cadrenal Therapeutics Inc. stock reversal real or fakeJuly 2025 PostEarnings & Community Consensus Trade Alerts - Newser
Can technical indicators confirm Cadrenal Therapeutics Inc.’s reversalMarket Trend Report & AI Optimized Trading Strategy Guides - Newser
Is Cadrenal Therapeutics Inc. showing signs of accumulationQuarterly Growth Report & Stepwise Trade Signal Guides - Newser
Using data tools to time your Cadrenal Therapeutics Inc. exitJuly 2025 EndofMonth & Accurate Entry/Exit Alerts - Newser
Cadrenal Therapeutics Inc. recovery potential after sell offInflation Watch & Verified Stock Trade Ideas - Newser
Will Cadrenal Therapeutics Inc. benefit from macro trends2025 Historical Comparison & Reliable Trade Execution Plans - Newser
Strategies to average down on Cadrenal Therapeutics Inc.Trade Entry Report & AI Forecasted Entry/Exit Points - Newser
News impact scoring models applied to Cadrenal Therapeutics Inc.Trade Risk Assessment & Weekly High Momentum Picks - Newser
Relative strength of Cadrenal Therapeutics Inc. in sector analysisJuly 2025 Setups & Low Risk Profit Maximizing Plans - Newser
Should you wait for a breakout in Cadrenal Therapeutics Inc.July 2025 Action & Stepwise Trade Signal Implementation - Newser
Is Cadrenal Therapeutics Inc. stock ready for a breakoutQuarterly Earnings Summary & Verified Swing Trading Watchlist - Newser
Best data tools to analyze Cadrenal Therapeutics Inc. stockJuly 2025 Levels & Community Trade Idea Sharing Platform - Newser
Will Cadrenal Therapeutics Inc. outperform its industry peersShort Setup & AI Enhanced Trading Alerts - Lancaster City Council
Is a relief rally coming for Cadrenal Therapeutics Inc. holdersTrade Volume Summary & Real-Time Buy Zone Alerts - Newser
What momentum shifts mean for Cadrenal Therapeutics Inc.Portfolio Value Summary & Stepwise Trade Execution Plans - Newser
Can momentum traders help lift Cadrenal Therapeutics Inc.2025 Short Interest & Comprehensive Market Scan Insights - Newser
Will Cadrenal Therapeutics Inc. outperform the marketJuly 2025 Momentum & Entry and Exit Point Strategies - Newser
Market reaction to Cadrenal Therapeutics Inc.’s recent newsJuly 2025 News Drivers & Weekly Chart Analysis and Trade Guides - Newser
Order flow analysis tools used on Cadrenal Therapeutics Inc.Quarterly Trade Review & Free Community Supported Trade Ideas - Newser
Is this a good reentry point in Cadrenal Therapeutics Inc.Earnings Growth Report & Precise Swing Trade Entry Alerts - Newser
Is Cadrenal Therapeutics Inc. stock overvalued or fairly priced2025 Dividend Review & Expert Curated Trade Ideas - 뉴스영
GOOS Flashes Rebound Signal in Oversold ConditionQuarterly Performance Summary & Technical Buy Zone Confirmations - beatles.ru
Long term hold vs stop loss in Cadrenal Therapeutics Inc.2025 Top Gainers & AI Enhanced Trading Alerts - Newser
Cadrenal Therapeutics Inc Stock (CVKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):